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SUMMARY
Precise regulation of the formation, maintenance,
and remodeling of the vasculature is required for
normal development, tissue response to injury, and
tumor progression. How specific microRNAs inter-
sect with and modulate angiogenic signaling cas-
cades is unknown. Here, we identified microRNAs
that were enriched in endothelial cells derived from
mouse embryonic stem (ES) cells and in developing
mouse embryos. We found that miR-126 regulated
the response of endothelial cells to VEGF. Addition-
ally, knockdown of miR-126 in zebrafish resulted in
loss of vascular integrity and hemorrhage during em-
bryonic development. miR-126 functioned in part by
directly repressing negative regulators of the VEGF
pathway, including the Sprouty-related protein
SPRED1andphosphoinositol-3kinase regulatorysub-
unit 2 (PIK3R2/p85-b). IncreasedexpressionofSpred1
or inhibition of VEGF signaling in zebrafish resulted in
defects similar tomiR-126 knockdown. These findings
illustrate that a single miRNA can regulate vascular
integrity and angiogenesis, providing a new target for
modulating vascular formation and function.
INTRODUCTION
The vascular network is composed of an intricate series of
vessels that serve as conduits for blood flow, regulate organ
growth, and modulate the response to injury. The vasculature
is also required for the expansion of tumor masses, as inhibi-
tion of new vessel formation prevents tumor growth. The
signaling and transcriptional pathways that govern vascular for-
mation are well studied, and that knowledge has formed the
basis for novel therapeutic approaches (Lien and Lowman,
2008).
Vascular endothelial cells initially differentiate from angioblas-
tic precursors and proliferate and migrate to form the primitive
vascular plexus through the process of vasculogenesis. This
network is further remodeled by angiogenesis and stabilized
by recruitment of pericytes and vascular smooth muscle cells
to form a functioning circulatory system. Several angiogenic
stimuli are essential to establish the circulatory system during
development and to control physiologic and pathologic angio-
genesis in the adult. For example, secreted growth factors,
including members of the vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and fibroblast
growth factor (FGF) families, bind tomembrane-bound receptors
and transmit signals through kinase-dependent signaling
cascades. These signals ultimately result in gene expression
changes that affect the growth, migration, morphology, and
function of endothelial cells.
How endothelial cells selectively respond to the wide variety of
angiogenic signals present in their microenvironment is poorly
understood. For example, exposure to VEGF induces the prolif-
eration of stalk cells in an angiogenic sprout, while inducing
directed migration, rather than proliferation, of cells at the tip.
One mechanism for modulating the endothelial response to
growth factors is through inhibition of downstream kinase signal-
ing cascades (Hellstrom et al., 2007; Jones et al., 2008). Sprouty
and Sprouty-related proteins are negative regulators of growth
factor signaling (reviewed in Mason et al., 2006). In particular,
Sprouty-related EVH1 domain-containing protein 1 (SPRED1)
negatively regulates the activation of the MAP kinase pathway
by binding and inactivating RAF1, an upstream kinase of the
pathway (Nonami et al., 2004; Taniguchi et al., 2007; Wakioka
et al., 2001).
Another potential mechanism by which endothelial cells may
regulate growth factor responses may be through the use of mi-
croRNAs. microRNAs are a class of small RNAs (!20–25 nt) that
regulate expression of target mRNAs posttranscriptionally, ei-
ther through translational inhibition or destabilization of target
mRNAs (reviewed in Wu and Belasco, 2008; Zhao and
Srivastava, 2007). A high degree of sequence complementarity
between the 50 end of the microRNA, known as the ‘‘seed’’ se-
quence, and themRNA is an important determinant of microRNA
targeting, as is the accessibility of the mRNA at the potential
binding site (Kertesz et al., 2007; Zhao et al., 2005).
Mice homozygous for a hypomorphic allele of Dicer, an en-
zyme essential for the biogenesis of most microRNAs, develop
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gross abnormalities during blood vessel development in the em-
bryo and in the yolk sac (Yang et al., 2005). While several broadly
expressed microRNAs regulate in vitro endothelial cell behavior,
including proliferation, migration, and the ability to form capillary
networks (Chen and Gorski, 2008; Kuehbacher et al., 2007; Lee
et al., 2007a; Poliseno et al., 2006; Suarez et al., 2007), the
in vivo functions of endothelial-specific microRNAs, or their tar-
gets, have yet to be described. By microRNA profiling of ES cell-
derived endothelial cells, we identified a group of endothelial-
enriched microRNAs, including miR-126, miR-146, miR-197,
and miR-625. These microRNAs were also enriched in endothe-
lial cells of developing mouse embryos. Through modulation of
the expression of miR-126 in vitro and in vivo, we demonstrate
that miR-126 positively regulates the response of endothelial
cells to VEGF. Furthermore, we show that miR-126 regulates
VEGF-dependent PI3 kinase and MAP kinase signaling by
directly targeting PI3KR2 (p85-b) and SPRED1, respectively,
two negative regulators of the VEGF signaling pathway.
RESULTS
miR-126 Is the Most Highly Enriched MicroRNA
in Endothelial Cells
To determine when the endothelial lineage first appears in dif-
ferentiating mouse ES cells in the embryoid body (EB) model,
extensive mRNA expression profiling was performed for endo-
thelial marker expression using quantitative reverse transcrip-
tase PCR (qRT-PCR). Oct4, a marker of pluripotent ES cells,
was rapidly downregulated during differentiation (data not
shown). At day 4 (d4) of EB formation, Flk1/Vegfr2 was dra-
matically induced, but other endothelial markers, such as
Tie2/Tek and CD31/Pecam1, were unchanged (Figure 1A).
This population of Flk1-positive cells at d4 contains vascular
precursor cells, as evidenced by the ability of isolated Flk1-
positive cells to differentiate into the endothelial lineage in
the presence of VEGF (data not shown). By d6 of EB forma-
tion, endothelial markers, including CD31 and Tie2, were
Figure 1. Identification of microRNAs Enriched in Endothelial Cells
(A) Gene expression changes were monitored by qRT-PCR during differentiation of mouse ES cells in an embryoid body (EB) model. Flk1 is expressed in vascular
progenitors and mature endothelial cells, while CD31 and Tie2 are markers of mature endothelial cells. Expression was normalized to Tata-binding protein (Tbp)
levels. The average of multiple experiments is shown.
(B) Endothelial cells were isolated from day 7 (d7) EBs by cell sorting with anti-CD31 antibodies andmicroRNA arrays were performed. microRNAs enrichedmore
than 1.5-fold relative to miR-16 in CD31+ cells compared to CD31" cells are shown.
(C) Enrichment of microRNAs identified in (B) in CD31+ endothelial cells sorted from E10.5 mouse embryos assayed by qRT-PCR.
(D) Expression of Egfl7, miR-126 and miR-126* in EBs assayed by qRT-PCR.
(E) miR-126 was enriched in sorted vascular progenitors (Flk1+) from d4 EBs and in endothelial cells (CD31+) from d7 EBs compared to ES cells. Tie2 expression
was used to assess mature endothelial gene expression in sorted cells used in (B) and (E).
Developmental Cell
miR-126 Regulates Angiogenic Signaling
Developmental Cell 15, 272–284, August 12, 2008 ª2008 Elsevier Inc. 273
robustly expressed and remained elevated even after 14 days
of differentiation.
We isolated CD31-positive and CD31-negative cells from d7
EBs by fluorescence-activated cell sorting (FACS) and profiled
microRNA expression by microarray. While several microRNAs,
including miR-146b, miR-197, miR-615, and miR-625, were
enriched more than 1.5-fold in CD31-positive cells, miR-126
was the most highly enriched microRNA (Figure 1B). MicroRNA
arrays were also performed at d14 of EB formation, and the
same subset of microRNAs was enriched (data not shown), sug-
gesting that relatively fewmicroRNAs are enriched in endothelial
cells.
To determine if these microRNAs were also enriched in endo-
thelial cells in vivo, we used FACS to isolate CD31-positive cells
from E10.5mouse embryos. qRT-PCRwith RNA from these cells
confirmed the enrichment of the above microRNAs, with the ex-
ception of miR-615, in CD31-positive cells compared to CD31-
negative cells from the same embryos (Figure 1C). Additionally,
miR-126*, expressed from the opposite strand of the miR-126
pre-miRNA, was also highly enriched in endothelial cells
in vivo, as was miR-146a, which differs from miR-146b by only
two nucleotides near the 30 end of the mature microRNA
(Figure 1C).
miR-126 is located in an intron of Egfl7, a gene that is highly
expressed in endothelial cells (Parker et al., 2004). The expres-
sion of Egfl7 largely mirrored that of endothelial markers during
EB formation (Figure 1D). Interestingly, expression of Egfl7,
miR-126, and miR-126* was induced at d4 of EB formation and
further increased at d6, when endothelial markers were robustly
expressed. miR-126 (Figure 1E) and miR-126* (data not shown)
were highly enriched in Flk1-positive vascular progenitors sorted
at d4 and were also enriched in mature CD31-expressing
endothelial cells at d7.
miR-126 Does Not Control Endothelial Lineage
Commitment
We have previously shown that the muscle-specific microRNA
miR-1 controls cell fate decisions of multipotent cells (Ivey
et al., 2008). Becauseof the early induction ofmiR-126 in vascular
progenitors, we investigated whether this microRNAmight regu-
late differentiation toward the endothelial lineage. We created
stable mouse ES cell lines that expressedmiR-126 under control
of the ubiquitously expressed EF1-a promoter (mESmiR-126) and
confirmed miR-126 overexpression (Figure S1A, available on-
line). The expression of several endothelial genes, including
Flk1, eNOS/NoS3, Tie2, and CD31, was not affected by miR-126
overexpression during ES cell differentiation (Figure S1B), and
the number of CD31-positive endothelial cells at d7 was not al-
tered (Figure S1C). This suggests that while miR-126 is enriched
in vascular progenitors, it is not sufficient to promote differentia-
tion of pluripotent cells toward the endothelial lineage.
miR-126 Modulates Endothelial Phenotype In Vitro
To study the loss-of-function of miR-126 in endothelial cells,
a morpholino (MO) antisense to miR-126 that spanned the
miR-126 50 Dicer cleavage site of the miR-126 pricursor was in-
troduced into human umbilical vein endothelial cells (HUVECs).
These cells expressed high levels of miR-126 (Figure S2A). Intro-
duction of the MO resulted in decreased levels of both mature
miR-126 andmiR-126* and an increase inmiR-126 pricursor, be-
ginning at 24 hr (h) posttransfection (Figure 2A and Figure S2B).
While both miR-126 and miR-126* were reduced to a similar ex-
tent, the absolute basal level of miR-126 was much higher than
miR-126* in endothelial cells (Figure S2C). Importantly, levels
of spliced EGFL7 mRNA, detected by qRT-PCR with primers
spanning the intron containing miR-126, and protein levels
of EGFL7, were unaffected by introduction of this MO
(Figure 2A).
Endothelial cells with reduced levels of miR-126 were pheno-
typically similar to control MO-transfected cells but had an
elevated rate of proliferation (Figure S3A). The endothelial pheno-
type was further studied in an in vitro wound closure or scratch
assay, in which the rate of migration of cells into a denuded
area of a confluent monolayer was monitored. Modulating miR-
126 levels had no effect on cell migration when complete me-
dium was used (Figure S3B). However, VEGF- (Figure 2B) and
bFGF-induced (Figure S3C) migration was inhibited in miR-126
knockdown cells compared to control MO-transfected cells.
Conversely, in cells transfected with miR-126 mimic, which ex-
press 50-fold moremiR-126, there was a trend toward increased
migration in response to VEGF stimulation (Figure 2B). Examina-
tion of the actin cytoskeleton revealed a reduction in large actin
filaments and more diffuse actin staining in many miR-126
knockdown cells (Figure 2C). Stimulation of endothelial cells
with VEGF normally results in the reorganization of the cytoskel-
eton, but this rearrangement was defective in miR-126 knock-
down cells (Figure S3D). Consequently, in scratch assays, there
was a reduction in cell protrusions into the denuded area in
knockdown cells (Figure 2D). These data suggest that endothe-
lial cell migration is regulated by miR-126 abundance.
The effect of miR-126 on the formation and stability of capillary
tubes on matrigel was also assessed. While initial formation of
tubes appeared normal, the capillary tubes were less stable
and appeared thin, with dissociation of many tubes after 24 hr
(Figure 2E). Assessment of cell adhesion bymeasuring the kinet-
ics of endothelial cell attachment (Figure S3E) and cell-cell junc-
tion formation by VE-cadherin immunostaining (data not shown)
revealed no obvious defects in miR-126 knockdown cells, sug-
gesting that the instability of tubes was not attributable to de-
fects in cell adhesion. To determine if there were survival defects
in cells with reduced levels of miR-126, cells were serum starved
in the presence or absence of VEGF. The number of control se-
rum-starved cells increased with addition of VEGF, but miR-126
knockdown cells were refractory to this increase in cell number in
response to VEGF (Figure 2F). TUNEL staining demonstrated
that VEGF treatment of control serum-starved cells resulted in
a decrease in apoptosis, but this effect was absent in miR-126
knockdown cells (Figure 2F).
miR-126 Regulates Blood Vessel Integrity In Vivo
Considering the dramatic effects of miR-126 on the behavior of
human endothelial cells in vitro, we assessed the in vivo function
of miR-126. For this purpose, we used zebrafish as a model sys-
tem in which a functioning cardiovascular system is not required
for viability through relatively advanced stages of embryogene-
sis. The mature forms of zebrafish miR-126 and miR-126* are
identical to their human orthologs. FACS isolation of GFP-posi-
tive cells from the endothelial cell-specific zebrafish reporter
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line Tg(flk1:GFP)s843 (Jin et al., 2007) demonstrated that miR-126
and miR-126* were highly enriched in zebrafish endothelial cells
(Figure 3A). As in human endothelial cells, miR-126 was more
abundant than miR-126* in zebrafish embryos (Figure 3B).
miR-126 expression was induced in 24 hr post fertilization (hpf)
embryos, was further increased at 48 hpf, and remained elevated
between 72 and 96 hpf (Figure 3C). We decreased miR-126 ex-
pression during zebrafish development by injecting two unique
morpholinos targeting pri-miR-126 (miR-126 MO1 and MO2
[Figure S4A]) into fertilized eggs. Injection of these MOs blocked
processing of pri-miR-126, resulting in a profound decrease in
mature levels of miR-126 and miR-126* (Figure 3D). Importantly,
levels of egfl7, which hosts one of the two copies of zebrafish
miR-126, and regulates tubulogenesis in zebrafish (Parker
et al., 2004), were not appreciably altered by the miR-126 MOs
(Figure 3D).
Figure 2. miR-126 Regulates Endothelial Phenotype In Vitro
(A) Relative levels of mature miR-126, spliced EGFL7 mRNA across the miR-126-containing intron, and EGFL7 protein (immunoblot) were measured 72 hr after
HUVECswere electroporatedwithmiR-126morpholinos (MOs) or control (con)MO.Densitometric analysis of EGFL7protein levels is indicated above immunoblot.
(B) The effect of miR-126 knockdown (MO) or overexpression (mimic) on endothelial cell migration in response to VEGF in the presence or absence of a VEGF
receptor inhibitor was determined by generating a ‘‘scratch’’ in a confluent monolayer of endothelial cells and measuring the degree of ‘‘wound closure’’ after 8
and 24 hr. Dashed lines indicate width of ‘‘wound.’’ Percent wound closure is shown as the mean ± SEM of five scratches from one representative experiment.
*p < 0.05 compared to control.
(C) Actin cytoskeletal structure was observed by phalloidin staining of control and miR-126 knockdown HUVECs.
(D) Actin staining revealed a decrease in cytoskeletal reorganization and cytoplasmic extensions into the denuded area in a scratch assay.
(E) Capillary tube formation of endothelial cells transfectedwith control ormiR-126MOsand seededontoMatrigel. Endothelial cells transfectedwithmiR-126MOs
formed capillary tubes, but these tubeswere unstable, exhibiting frequent dissociation of tubular structures compared to control. Shown is a representative image
at 24 hr after plating. Arrows indicate examples of broken tubes. Quantification of the average number of tubes per field of view at 4 hr and the number of complete
and broken tubes at 24 hr from a representative experiment is shown below.
(F) VEGF-mediated changes in cell number and cell death by TUNELwere assessed in control andmiR-126 knockdown cells. VEGF treatment increased total cell
number and decreased the percent of serum-starved cells that were TUNEL positive, but this effect was absent in cells with reduced levels of miR-126. * denotes
a significant difference between VEGF treated and non-treated cells (p < 0.05).
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Through the use of Tg(flk1:GFP)s843; Tg(gata1:dsRed)sd2
zebrafish, which express GFP in the vasculature, and dsRed in
blood cells, we assessed the effect of miR-126 knockdown on
vascular development and circulation. No differences in gross
morphology (Figure 3E, top panel) or vascular patterning (Fig-
ure 3E, middle panel) were evident between control andmiR-126
morpholino-injected (morphant) embryos. Additionally, FACS
quantification revealed no significant difference in the percent-
age of Tg(flk1:GFP)s843-expressing endothelial or Tg(gata1:
dsRed)sd2-expressing blood cells in control, miR-126 MO1, or
miR-126 MO2-injected zebrafish (Figure S4B). However, several
abnormalities were evident in the circulation and vessel mor-
phology. These defects occurred in 70% ± 5% (n = 60 per
experiment, 3 independent experiments) of the miR-126 MO-
injected embryos and were similar with either MO. While circula-
tion of blood occurred normally between 24 and 36 hpf, the
presence of Tg(gata1:dsRed)sd2-expressing blood cells in the
head vasculature, intersomitic vessels (ISVs), dorsal aorta (DA),
and primary cardinal vein (PCV) was reduced between 36 and
72 hpf (Figures 3E, bottom panel, and 3F; data not shown). Blood
cells were made and were visible in the heart at these time
points (Figures 3E and 3F). Severe cranial hemorrhages were
Figure 3. miR-126 Regulates Vascular Integrity and Lumen Maintenance In Vivo
(A) miR-126 and miR-126* enrichment (qRT-PCR) in GFP+ endothelial cells from 72 hpf Tg(flk1:GFP)s843 zebrafish compared to GFP" cells.
(B) Relative levels of miR-126 and miR-126* in 72 hpf zebrafish embryos.
(C) miR-126 expression monitored by qRT-PCR during zebrafish development.
(D) Levels of miR-126/126* or egfl7 (across intron containing miR-126) quantified by qRT-PCR in 72 hpf zebrafish injected with miR-126 MOs relative to control.
(E) Lateral views of control and miR-126 MO-injected Tg(flk1:GFP)s843; Tg(gata1:dsRed)sd2 zebrafish (72 hpf). Brightfield microscopy (top) revealed no major
changes in gross morphology, while flk1:GFP showed normal blood vessel patterning (middle). Presence of blood cells (gata1:dsRed) in the intersomitic vessels
(isv), dorsal aorta (da) and primary cardinal vein (pcv) was greatly reduced in morphants (bottom). y, yolksac; h, head; ht, heart.
(F) miR-126morphants (48 hpf) had normal vessel patterning (flk1:GFP), but developed cranial hemorrhages (gata1:dsRed; arrow) in the head. baa, branchial arch
arteries.
(G) Ventral view of baa suggested smaller luminal size in miR-126 morphants.
(H) Transverse section of control or miR-126 MO-treated zebrafish revealed that the da and pcv of morphants had a smaller lumen than controls; higher
magnification (right panels) of boxed area shows collapsed da and small pcv in morphants. flk1:GFP, green; ZO-1, an epithelial marker, red.
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also present in 20% ± 3% (n = 60 per experiment, 3 independent
experiments) of embryos, evidenced by the accumulation of
dsRed-positive cells (Figure 3F). Importantly, cardiac contractile
function was not grossly affected by miR-126 MO at either 48
or 72 hpf.
We observed that some Tg(gata1:dsRed)sd2-expressing cells
were trapped in the ISVs of miR-126 morphants (data not
shown), indicating that blood vessel integrity might be compro-
mised. Indeed, branchial arch vessels (Figures 3F and 3G)
appeared to have a reduced lumen diameter in morphants. To
better characterize these defects, we analyzed the integrity of
endothelial tubes by examining the DA and PCV in miR-126 mor-
phants by confocal microscopy (Figure 3H). These experiments
revealed collapsed lumens and compromised endothelial tube
organization in miR-126 morphants, suggesting that miR-126
expression was required to maintain vessel integrity and caliber
during zebrafish vascular development.
Identification of Genes Regulated by miR-126
by Microarray
AlthoughmiR-126morphants had severe defects in vessel integ-
rity, the number of endothelial cells was not altered. We took
advantage of this phenotype and isolated Tg(flk1:GFP)s843-
expressing endothelial cells by FACS from control and miR-126
MO1- and MO2-injected zebrafish and analyzed mRNA expres-
sion by microarray. Since similar genes were altered in miR-126
MO1- andMO2-injected zebrafish, the data sets were combined
to identify dysregulated genes in miR-126 morphants (see Ta-
bles S1 and S2 for up- and downregulated genes, respectively).
By gene ontology (GO) statistical analysis, themost highly dysre-
gulated class of genes in the endothelium of miR-126 morphants
encoded transcription factors (Table S3). The homeobox (HOX)
and forkhead box (FOX) family of genes were especially affected
in miR-126 morphants, many of which regulate endothelial cell
biology, including angiogenesis (Bruhl et al., 2004; Dejana
et al., 2007; Myers et al., 2000).
Microarray analysis was also performedwith RNA from human
endothelial cells (HUVECs) in which miR-126 was knocked down
for 72 hr (see Tables S4 andS5 for up- and downregulated genes,
respectively). The most overrepresented GO terms were related
to the cell cycle and the cytoskeleton (Table S6). This observation
supports our finding that cells with reduced levels of miR-126
proliferated more rapidly than control cells and had altered cyto-
skeletal structures (Figure S3A and Figures 2C and 2D). Platelet-
derived growth factors (PDGF) A, B, C, and D, which are impor-
tant in endothelial biology, were all significantly downregulated
in cells with reduced levels of miR-126 (Table S6; data not
shown). In addition, genes categorized as important for vascular
development were highly dysregulated (Table S6). A total of 61
genes were similarly altered (p < 0.05) in zebrafish and human
miR-126 knockdown expression arrays (data not shown), sug-
gesting a high conservation in the gene repertoire regulated by
miR-126. To determine how many of the upregulated genes in
miR-126 knockdown endothelial cells might be direct miR-126
targets, we performed bioinformatic analyses of miR-126 and
miR-126* seed matches in the 30 UTRs of genes upregulated by
>1.5-fold in human cells with reduced levels of miR-126. miR-
126seedmatcheswerehighly enriched in theupregulatedgenes,
while seedmatches formiR-126* or anunrelatedmicroRNA,miR-
124, were not enriched (Figure S5). Surprisingly, genes contain-
ing both miR-126 andmiR-126* seedmatches were also statisti-
cally overrepresented, while the combination of miR-126 and
miR-124 seed matches was not. This suggests that miR-126
and miR-126*, which are derived from the same pri-miRNA,
coordinately regulate target genes.
miR-126 Regulates EGFL7 Expression in a Negative
Feed-Back Loop
EGFL7mRNA was highly upregulated on the human array (Table
S4) despite our earlier finding that levels of spliced EGFL7mRNA
and protein were unchanged (Figure 2A). To understand this
discrepancy, we used qRT-PCR with primer sets specific for
the transcriptional start sites of the threeEGFL7 isoforms (named
here EGFL7 isoform A, B, and C, all of which contain the same
open reading frame [ORF]), as well as several primer sets that
were common to all three isoforms. EGFL7mRNA levels were in-
creased throughout the EGFL7 transcriptional unit (Figure S6A),
except for the spliced EGFL7 mRNA surrounding the miR-126-
containing intron, as we noted earlier (Figure 2A). Thus, EGFL7
wasupregulated inmiR-126MO-treated cells, but theMOappar-
ently inhibited processing of the intron containing miR-126, re-
sulting in no net change in EGFL7 protein levels. Only EGFL7 iso-
form B was induced by miR-126 MO (Figure S6A). Since all three
isoforms contain the same30 UTR,miR-126may regulate isoform
B in a 30 UTR-independent fashion. By performing RNA polymer-
ase II (Pol II) chromatin immunoprecipitation (ChIP) experiments,
we noted an increase in Pol II density at the promoter of isoformB
and in the coding region (which is common to all three isoforms),
but not at the promoter of isoform A, which was not induced by
miR-126MO (Figure S6B). Thus,miR-126may indirectly regulate
EGFL7 isoform B at the transcriptional level.
miR-126 Represses SPRED1, VCAM1, and PIK3R2
Posttranscriptionally
To understand the mechanisms by which miR-126 regulates en-
dothelial biology, we searched for potential direct mRNA targets
of miR-126. Several miRNA target prediction algorithms were
employed, including one developed in our lab that incorporates
sequence complementarity and mRNA target site accessibility
(K. Ivey and D.S., unpublished data). Portions of the 30 UTR of
several potential targets were cloned into the 30 UTR of a lucifer-
ase construct, and the ability of miR-126 to affect luciferase ex-
pression was determined in HeLa cells, which do not normally
express miR-126. Six potential targets were initially chosen
based on binding sites (Figure S7) and a known role in endothe-
lial cell signaling or vascular function. These included regulator of
G protein signaling 3 (RGS3) (Bowman et al., 1998; Lu et al.,
2001), SPRED1 (Wakioka et al., 2001), PIK3R2 (also known as
p85-b) (Ueki et al., 2003), CRK (Park et al., 2006), integrin
alpha-6 (ITGA6), and vascular cell adhesion molecule 1
(VCAM1). miR-126, but not a control miRNA, miR-1, significantly
repressed the activity of luciferase derived fromRNAs containing
the 30 UTR of SPRED1, VCAM1, and PIK3R2 (Figure 4A).
Luciferase experiments were also performed in endothelial
cells in which endogenous miR-126 levels were knocked down
by antisense MO. The activity of luciferase from constructs
that included portions of the SPRED1, VCAM1, or PIK3R2 30
UTR was increased upon knockdown of miR-126 (Figure 4B).
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In contrast, a MO directed to miR-21, which is also expressed in
endothelial cells, had no effect on the activity of the constructs
tested (data not shown).
MicroRNAs can regulatemRNA stability or translation of target
mRNAs. We quantified mRNA expression of potential miR-126
targets by qRT-PCR in HUVECs that had been transfected with
antisense miR-126 MO or a miR-126 mimic (Figure 4C). While
SPRED1 and PIK3R2 mRNA levels were reciprocally regulated
by miR-126 abundance, VCAM1 mRNA levels were elevated
upon miR-126 inhibition but were not decreased in the presence
of miR-126 mimic. As a control, we examined levels of RGS3,
since the 30 UTR of this gene did not affect luciferase activity in
the presence of miR-126. RGS3 expression was unchanged
when miR-126 levels were modulated (Figure 4C). We also as-
sessed the expression of SPRED1, PIK3R2, and VCAM1 protein
Figure 4. Identification of miR-126 mRNA
Targets
(A) Relative luciferase activity of constructs con-
taining the 30 UTR of potential miR-126 targets in-
troduced into HeLa cells in the presence of miR-1
or miR-126. The 30 UTR was also inserted in the
antisense orientation as a control (control 30
UTR). Firefly luciferase activity for each construct
was normalized to the co-transfected Renilla lucif-
erase construct and then normalized to the
change in pGL3 luciferase in the presence of
microRNA. For each 30 UTR construct, normalized
luciferase activity in the absence of microRNAwas
set to 1. * p < 0.05 compared to pGL3.
(B) Relative luciferase activity of select constructs
in (A) in HUVECs upon inhibition of miR-126 with
MOs. Normalization was performed as in (A).
(C) mRNA levels of potential targets in HUVECs
transfected with miR-126 mimic or MO quantified
by qRT-PCR. Values are relative to transfection
controls.
(D) Immunoblot of SPRED1, VCAM1, and PIK3R2
protein in control or miR-126 MO-transfected
HUVECs 72 hr post-transfection. GAPDH is shown
as a loading control.
(E) Sequence complementarity of a potential miR-
126 binding site in the zebrafish spred1 30 UTR.
(F and G) Luciferase assays (as in (A) and (B),
respectively) using the zebrafish spred1 30 UTR.
by western blot after introduction of con-
trol or miR-126MOs (Figure 4D). SPRED1
and PIK3R2 protein were increased
when miR-126 levels were decreased
(Figure 4D). However, we could not de-
tect VCAM1 protein in either control or
miR-126 MO-transfected endothelial
cells. This was not due to an ineffective
antibody, since VCAM1protein was read-
ily detectible in TNF-a-treated endothelial
cells (data not shown). Indeed, VCAM1
has recently been identified as a miR-
126 target in TNF-a-treated endothelial
cells (Harris et al., 2008).
The 30 UTR of zebrafish spred1 con-
tains a highly conserved 8-mer that is
perfectly complementary to nucleotides 2–9 of miR-126
(Figure 4E). Addition of miR-126 specifically repressed the activ-
ity of luciferase reporters containing this 30 UTR (Figure 4F). Con-
versely, knockdown of miR-126 led to an increase in luciferase
activity of the spred1 30 UTR luciferase construct when trans-
fected into HUVECs (Figure 4G). This suggests that miR-126 tar-
geting of Spred1 is conserved in zebrafish.
miR-126 Modulates VEGF-Dependent Events
by Targeting SPRED1 and PIK3R2
SPRED1 and PIK3R2 negatively regulate growth factor signaling
via independent mechanisms. SPRED1 functions by inhibiting
growth factor-induced activation of the MAP kinase pathway
(Taniguchi et al., 2007), while PIK3R2 is thought to negatively
regulate the activity of PI3 kinase (Ueki et al., 2003). Activation
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of theMAP and PI3 kinase pathways by growth factor stimulation
can be assessed by measuring the phosphorylation status of
ERK and AKT, two respective downstream targets of these path-
ways. We found that the VEGF-induced phosphorylation of ERK
and AKT was attenuated in miR-126 knockdown cells
(Figure 5A). In contrast, phosphorylation of SRC was unaffected
by modulation of miR-126, suggesting that some arms of the
VEGF signaling pathway were unaffected by miR-126 knock-
down (Figure 5A). Activation of ERK and AKT in response to
EGF and bFGF-stimulation was also reduced in miR-126 knock-
down cells in vitro (Figure S8A). However, the defects in signaling
downstream of EGF and bFGF were less pronounced than sig-
naling downstream of VEGF. In contrast, MAP kinase signaling
downstream of TNF-a was unaffected (Figure S8B).
To determine if SPRED1 and PIK3R2 are involved in
miR-126-dependent signaling defects, we knocked these genes
down in cells with reduced levels of miR-126. The defect in
VEGF-dependent AKT phosphorylation was rescued by siRNA-
mediated knockdown of PIK3R2 (Figure 5B), while inhibition
of SPRED1 rescued the defect in ERK phosphorylation
(Figure 5C). We also investigated whether decreasing SPRED1
expression in miR-126 knockdown cells could rescue the
VEGF-dependent migration defect described earlier (Figure 2B).
While SPRED1 MO alone had no effect on VEGF-induced endo-
thelial cell migration, the knockdown of SPRED1 protein largely
rescued the migration defect in cells with decreased miR-126
expression (Figure 5D).
To test whether decreased VEGF signaling in vivo would result
in a defect in vascular maintenance similar to miR-126 knock-
down, we treated 48 hpf embryos, which have a fully functioning
circulatory system, with a VEGF receptor inhibitor (Chan et al.,
2002). After 18 hr, >90% of treated embryos displayed severe
circulatory defects, including collapsed vessels (Figure 5E and
Figure S9A). The amount of blood in the embryos was the
same as that of vehicle-treated controls (data not shown). Circu-
lation in the ISVs (Figure 5E) and in the head vasculature (data not
shown) was absent or severely diminished, and more than 15%
of the embryos also developed hemorrhages (Figure 5F). This
phenotype was similar in many respects to miR-126 morphant
embryos.
Figure 5. miR-126 Positively Regulates
VEGF Signaling in Endothelial Cells by
Repressing SPRED1 and PIK3R2
(A) Immunoblot of lysates from HUVECs trans-
fected with control or miR-126 MOs in the pres-
ence or absence of VEGF (10 ng/ml, 10 min).
VEGF induced phosphorylation of ERK (p-ERK)
and AKT (p-AKT), which was blocked by miR-
126 inhibition. Total levels of ERK and AKT were
not affected. Phosphorylation of SRC was not
affected by miR-126 knockdown. Densitometric
analysis of normalized protein levels are indicated
above immunoblot.
(B) PIK3R2 mRNA was knocked-down by RNAi in
HUVECs transfected with control or miR-126 MOs
(qRT-PCR).Western analysis indicates a decrease
in PIK3R2 protein by introduction of siRNA, even in
the presence of miR-126 MOs. Knockdown of
PIK3R2 rescued the defect in VEGF-dependent
phosphorylation of AKT in miR-126 MO-treated
cells.
(C) Western analysis shows reduced SPRED1
levels by transfection of a MO that blocks SPRED1
translation, even in the presence of miR-126 MO.
SPRED1 MO rescued the defect in VEGF-induced
phorphorylation of ERK in miR-126 MO-trans-
fected cells.
(D) Quantification of percent (%) wound closure of
endothelial cells in a ‘‘scratch’’ assay reveals res-
cue of miR-126 MO effects by knocking down
SPRED1. * p < 0.05 compared to control MO.
(E) Treatment of 48 hpf embryos with a VEGF
receptor inhibitor (Vatalanib, 5 mM, 18 hr) re-
sulted in reduced circulation of blood cells
(gata1:dsRed). ISVs (flk1:GFP) appeared to lack
a lumen after VEGF inhibition.
(F) Hemorrhages also occurred in some embryos
treated with VEGF receptor inhibitor (arrow).
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Increased Spred1 in Zebrafish Disrupts Vascular
Integrity Similar to miR-126 Knockdown
To determine whether excess Spred1 in zebrafish could cause
vascular defects similar to those caused by miR-126 inhibition,
we injected spred1 mRNA, which is expressed in endothelial
cells (Figure S9B), into zebrafish embryos. Consistent with the
known function of Spred1, spred1 mRNA-injected embryos
had decreased levels of phosphorylated ERK compared to con-
trol (hapd1) mRNA-injected fish, suggesting diminished growth
factor signaling (Figure 6A). Additionally, transfection of COS-1
cells with an expression construct containing zebrafish spred1
cDNA resulted in dramatically reduced levels of phosphorylated
ERK, confirming that zebrafish Spred1, like its mammalian
counterpart, negatively regulates the MAP kinase pathway
(Figure 6B). Gastrulation defects occurred inmany of the spred1-
and control mRNA-injected embryos. However, the remaining
embryos appeared grossly normal and were analyzed further.
Vascular patterning as assessed by Tg(flk1:GFP)s843 expression
was relatively normal in the majority of spred1 mRNA-injected
embryos (Figure 6C, left panels). However, the presence of blood
cells marked by Tg(gata1:dsRed)sd2 expression was markedly
decreased in the ISVs, DA, and PCV (Figure 6C, right panels).
Greater than 20%of the embryos developed cranial and pericar-
Figure 6. Increased Spred1 Causes Vascu-
lar Instability and Hemorrhage Similar to
miR-126 Knockdown
(A) Levels of phosphorylated Erk were reduced in
zebrafish embryos (8 hpf) injected with spred1
mRNA compared to control mRNA (hadp1).
Densitometric analysis is shown above.
(B) Zebrafish Spred1, but not Hadp1, expression
also reduced p-ERK in COS cells as observed by
immunoblot.
(C) Lateral view of trunk region of 48 hpf em-
bryos after injecting 100 pg of control (hadp1)
or spred1 mRNA. flk1:GFP reveals normal vas-
cular patterning but gata1:dsRed shows
diminished blood cells in the dorsal aorta (da),
primary cardinal vein (pcv), and intersomitic
vessels (isv).
(D) Injection of spred1mRNA also resulted in peri-
cardial (2nd panel from right) and cranial (far right)
hemorrhages (arrows) visualized by gata1:dsRed
marking of blood cells, and edema (2nd panel
from left).
(E) Confocal analysis of transverse sections of
48 hpf embryos revealed collapsed lumens of da
and primary cardinal vein (pcv) in spred1-injected
embryos.
dial hemorrhages, indicating the pres-
ence of blood cells but the lack of vascu-
lar integrity (Figure 6D). Additionally,
confocal analysis revealed collapsed
blood vessels, similar to miR-126 mor-
phants (Figure 6E). The phenotypic and
functional similarities in embryos with in-
creased expression of Spred1 compared
to those with increased Spred1 second-
ary to miR-126 inhibition suggests that
Spred1 may be a major mechanism by which miR-126 regulates
vascular integrity.
We attempted to test whether knockdown of Spred1 (Fig-
ure S9C) could rescue the vascular defects in miR-126 mor-
phants but observed severe consequences of Spred1 inhibition.
Embryos injected with a Spred1 splice-blocking (sb)MO (Spred1
MOsb) developed cranial hemorrhages and pericardial edema,
even at low doses ofMO (Figure S9D). A second, nonoverlapping
translation-blocking morpholino (Spred1 MOATG) also resulted
in pericardial edema (data not shown).
DISCUSSION
Here we have shown that miR-126 regulates many aspects of
endothelial cell biology, including cell migration, organization
of the cytoskeleton, capillary network stability, and cell sur-
vival, and demonstrate that miR-126 is required for the main-
tenance of vascular structure in vivo. miR-126 directly targets
SPRED1, VCAM1, and PIK3R2 for repression and functions to
promote VEGF signaling by inhibiting SPRED1 and PIK3R2.
The identification of an endothelial-specific microRNA that
regulates angiogenic signaling and vascular integrity repre-
sents an advance that has implications for many aspects of
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biology, including development, cancer, and tissue response
to injury.
miR-126 (Kloosterman et al., 2006; Wienholds et al., 2005) and
its host transcript,Egfl7 (Parker et al., 2004), are highly expressed
in endothelial cells. Our analysis of miR-126 function suggests
that Egfl7 and miR-126 play somewhat related, yet temporally
and functionally distinct, roles in zebrafish vascular development.
The initial patterning of the zebrafish vasculature appeared unaf-
fected in miR-126 morphants, yet miR-126 morphants displayed
a profound loss of lumenized blood vessels by 48 hpf.While Egfl7
morphants alsohavedefects in lumenization, thesedefects occur
very early and involve the inability of angioblasts to initially form
a lumen during tubulogenesis (De Maziere et al., 2008; Parker
et al., 2004). While it is not known whether knockdown of Eglf7
also affects miR-126 levels, it is unlikely that miR-126 dysregula-
tion contributes significantly to the Egfl7 morphant phenotype,
since rescue can be achieved by injection of egfl7mRNA, which
lacks miR-126 sequences (Parker et al., 2004). It is interesting
that the egfl7 transcriptional unit may have multiple roles in regu-
lating lumenization, with Egfl7 regulating the formation, and miR-
126 the maintenance, of the vascular lumen.
Our finding that miR-126 directly targets SPRED1 and PIK3R2
provides important evidence that the VEGF pathway can be reg-
ulated at multiple levels by a microRNA (Figure 7). Cells with re-
duced levels of miR-126 were less responsive to VEGF and other
growth factors. SPRED1 inhibits activity of the RAF1 kinase (Wa-
kioka et al., 2001), but its function in the vasculature is only par-
tially understood. For example, Spred1 and Spred2 redundantly
control lymphangiogenesis during mouse development by
negatively regulating Vegfr-3 signaling (Taniguchi et al., 2007).
miR-126-dependent defects in ERK phosphorylation and cell
migration were partially rescued by MO-based inhibition of
SPRED1 translation, indicating that miR-126 regulates VEGF
signaling, in part, through SPRED1.
miR-126 regulation of VEGF and other growth factor signaling
appears to be reinforced by targeting of PIK3R2 (p85-b), which
negatively regulates the activity of PI3 kinase (Ueki et al., 2003).
A role for PIK3R2 in the regulation of VEGF signaling had not
previously beenaddressed. Importantly,we found that siRNA-me-
diated knockdown of PIK3R2 in cells with reducedmiR-126 levels
was able to rescue the defect in VEGF-dependent AKT phosphor-
ylation, indicating the significance of PIK3R2 as a target. These
findings support the emerging theme of microRNAs functioning
as ‘‘master regulators’’ of key pathways by their ability to
target multiple mRNAs in a coordinate fashion (Silver et al., 2007;
Zhao et al., 2007).
Other genes regulated by miR-126 may also contribute to the
attenuation of growth factor responsiveness in cells with lower
levels of miR-126. For example, the downregulation of PDGF-A,
-B, -C, and -D in human cells upon inhibition of miR-126 was
striking given the role of PDGFs in promoting angiogenesis
(Cao et al., 2002; Guo et al., 2003; Li et al., 2003). Similarly,
EphrinB2, which inhibits MAP kinase signaling downstream of
VEGF (Kim et al., 2002), was upregulated in both human and
zebrafish endothelial cells with reduced miR-126 expression.
Finally, RGS5, which represses phosphorylation of ERK (Cho
et al., 2003), and Rgs4, a closely related RGS protein that inhibits
tubulogenesis by reducing ERK phosphorylation (Albig and
Schiemann, 2005), were upregulated in endothelial cells with de-
creased miR-126 expression. Thus, the alteration of numerous
genes involved in angiogenic signaling pathways in response
to miR-126 inhibition suggests a global effect of this microRNA
on titrating growth factor signals.
Recent studies in the mouse have illustrated that autocrine
VEGF signaling in endothelial cells is essential for vascular
homeostasis (Lee et al., 2007b). In mice with VEGF deleted
from the endothelium, blood vessels were highly abnormal,
and hemorrhages occurred in multiple vascular beds. Interest-
ingly, the lumens of several blood vessels appeared to be col-
lapsed in VEGF mutants. This phenotype is similar in many
respects to zebrafish with reduced miR-126, and inhibition of
VEGF signaling after the establishment of circulation produced
similar defects in zebrafish embryos. We propose that increased
expression of the miR-126 targets SPRED1 and PIK3R2 in the
endothelium of miR-126 morphants inhibits VEGF signaling
(Rousseau et al., 2000). Since SPRED1 also regulates the cyto-
skeleton (Johne et al., 2008;Miyoshi et al., 2004), themechanism
responsible for vessel collapse in miR-126 morphants may
involve disruption of cytoskeletal structure. In support of this hy-
pothesis, we noted that several cytoskeletal genes were dysre-
gulated in cultured endothelial cells with reduced miR-126
and that the arrangement of actin fibers in basal and VEGF-
stimulated endothelial cells was defective.
Our findings have important implications not only for vascular
development but also for tumor biology. We have shown that
angiogenic signaling and vascular integrity can be disrupted
through modulation of miR-126 expression. Interestingly, EGFL7
is downregulated in quiescent endothelial cells but is upregu-
lated in the endothelium of proliferating tissue, including tumors
(Parker et al., 2004). Since miR-126 is embedded within EGFL7,
it is possible that miR-126 increases the sensitivity of these
activated endothelial cells to VEGF or other growth factors
through repression of SPRED1 and/or PIK3R2 expression. Thus,
miR-126 may contribute to angiogenesis in this setting. Con-
sidering the importance of miR-126 in the regulation of angio-
genesis and vascular integrity, we propose that miR-126 may
be an important target for either pro- or antiangiogenic therapies.
Figure 7. Putative Model of miR-126 Function in Endothelial Cells
miR-126 represses SPRED1 and PIK3R2, which negatively regulate VEGF sig-
naling (and possibly other growth factor signaling pathways) via the MAP ki-
nase and PI3 kinase pathways, respectively. Thus, miR-126 promotes VEGF
signaling, angiogenesis and vascular integrity by inhibiting protein production
of endogenous VEGF repressors within endothelial cells.
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EXPERIMENTAL PROCEDURES
Cell Biology Assays
For a detailed description of cell culture and endothelial cell biology assays (cell
survival, adhesion, migration, tube formation), please see the Supplemental
Data.
Fluorescence-Activated Cell Sorting
Single-cell suspensions were generated by digesting EBs or mouse embryos
with Accutase (Chemicon). Cells were resuspended in PBS containing 1%
BSA and labeled with fluorochrome-conjugated primary antibodies. For the
separation of Flk1-positive cells from mouse EBs, phycoerytherin (PE)-conju-
gated anti-mouse Flk1 antibody (BD PharMingen, Avas 12a, catalog number
555308) was used. For the separation of CD31-positive cells from mouse
EBs or embryos, FITC-conjugated anti-mouse CD31 antibody (BD PharMin-
gen, MEC 13.3, catalog number 553372) was used. Antibodies were used at
5 mg/ml and were incubated with cells for 30 min at 4#C with rotation; cells
were then washed with PBS-1% BSA. Cells were sorted in PBS-0.1% BSA
with a FACS Diva flow cytometer and cell sorter (Becton Dickinson). For the
sorting of endothelial cells from Tg(flk1:GFP)s843 zebrafish, embryos were
digested with trypsin and sorted based on GFP fluorescence.
Transfection/Electroporation of Plasmids, MOs, and MicroRNA
Mimics
HeLa cells were transfected using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s recommendations. Cells were transfected at 90% con-
fluency in 6-well dishes with 2 mg pGL3 (empty or with 30 UTR of potential tar-
gets inserted), 2 mg expression construct (empty or with miR-1 or miR-126 pri-
cursor sequence), and 0.1 mg Renilla construct (for normalizing transfection
efficiency). Cells were analyzed at 48 hr posttransfection.
HUVECs (0.53 106) were electroporated using the Amaxa Nucleofector ac-
cording to the manufacturer’s recommendations with 15 nmol control MO or
MOs that block processing of the miR-126 pricursor or translation of SPRED1
(Gene Tools; see below for sequences). For rescue experiments, HUVECs
were coelectorporated with 15 nmol control or miR-126 MOs together with
15 nmol SPRED1 MO. For luciferase experiments, HUVECs were electro-
porated with 1 mg pGL3 luciferase constructs and 0.5 mg Renilla construct,
together withMOs. Cells were analyzed 72 hr posttransfection. For transfection
of endothelial cells with miR-126 mimic, Oligofectamine (Invitrogen) was used
according to the manufacturer’s recommendations with 300 nM control or
miR-126 mimic (Dharmacon). Cells were analyzed 48 hr posttransfection.
For siRNA-mediated knockdown of PIK3R2, endothelial cells were trans-
fected with 300 nM Stealth siRNA (top strand: 50-UUG UCG AUC UCU CUG
UUG UCC GAG G-30) or a GC-matched control (Invitrogen) using Oligofect-
amine. For rescue experiments, HUVECs were electroporated with control
or miR-126 MO using the Amaxa kit and 24 hr later were transfected with
control or PIK3R2 siRNAs. Analysis of protein or RNA was performed after
an additional 48 hr.
Luciferase Assays
Firefly and Renilla luciferase activities were quantified in lysates using the Dual
Luciferase Reporter Assay kit (Promega) on a Victor3 1420 multilabel counter
(PerkinElmer) according to the manufacturer’s recommendations. Luciferase
readings were corrected for background, and Firefly luciferase values were
normalized to Renilla to control for transfection efficiency.
Microarrays and Quantitative Reverse-Transcriptase Real-Time
PCR (qRT-PCR)
For detailed methods, please see the Supplemental Data.
Chromatin immunoprecipitation (ChIP)
ChIP was performed essentially as described (Fish et al., 2005). For detailed
methods, please see the Supplemental Data.
Zebrafish Experiments
Tg(flk1:GFP)s843;Tg(gata1:dsRed)sd2 zebrafish embryos (Jin et al., 2007) were
injected at the one-cell stage with 1–2 ng Spred1 splice-blocking or translation
blocking MOs (see sequences below). For miR-126 MOs, embryos were in-
jected with 4–8 ng MO. For spred1 mRNA injection, full-length zebrafish
spred1 was cloned into pcDNA3.1. mRNA was generated by T7 mMessage
mMachine (Ambion), and 100 pg mRNA was injected into embryos. As a
control, zebrafish heart adaptor protein 1 (hadp1) mRNA (accession number
EU380770) was synthesized and injected in parallel. While development was
essentially normal with 100 pg injected hadp1, developmental abnormalities
were evident at higher amounts of injected mRNA (J.W. and D. Li, unpublished
data). Embryo development was assessed at 24–72 hpf. For VEGF receptor in-
hibitor treatment, 48 hfp embryos were treated with 5 mM Vatalanib (LC Labo-
ratories) in DMSO. Control embryos were treated with the same volume of
DMSO alone.
Morpholinos
MOs targeting dre-pri-miR-126 were 50-TGC ATT ATT ACT CAC GGT ACG
AGT TTG AGT C-30 (dre-miR-126 MO-1) and GCC TAG CGC GTA CCA AAA
GTA ATA A (dre-miR-126 MO-2), and those targeting hsa-miR-126 were
GCA TTA TTA CTC ACG GTA CGA GTT T (hsa-miR-126 MO). To direct non-
sense-mediated decay of zebrafish spred1, a MO was designed to cause
exon 2 skipping and the generation of a premature stop codon. The MO was
CCT GAG GAC CAG AAA CAG TCT CAC C (zebrafish Spred1 MOsb). A sec-
ond, nonoverlapping MO was used to block translation of zebrafish spred1:
GTT CTT CGC TCA TGT TTC TCT CAC G (zebrafish Spred1 MOATG). To block
translation of human SPRED1, the following MO was used: GTC TCC TCG
CTC ATC TTT CCC TCA C (human SPRED1 MOATG).
Western Blotting
Western blots were performed with 20–40 mg protein. The antibodies used
were anti-AKT1 (Santa Cruz), -phospho-AKT1/2/3 (Ser473) (Cell Signaling),
-ERK2 (Santa Cruz), -phospho-ERK1/2 (Thr202/Tyr204) (Cell Signaling), SRC
(Cell Signaling), -phospho-SRC (Tyr416) (Cell Signaling), -EGFL7 (Santa Cruz
or Abnova), -SPRED1 (Abgent and kindly provided by Dr. Yoshimura),
-PIK3R2 (Abcam), -GAPDH (Santa Cruz), and -VCAM1 (Santa Cruz). For phos-
pho-AKT, -ERK, and -SRC western blots, HUVECs were serum-starved in
medium containing 0.1% FBS without growth factors overnight and then stim-
ulated with 10 ng/ml human recombinant VEGF (BD Biosciences), EGF (R&D
Systems), bFGF (Invitrogen), or 50 ng/ml TNF-a (R&D Systems) for 10 min.
Statistical Analyses
All experiments were repeated aminimum of three times, and the error bars on
graphs represent the mean ± the standard error of the mean, unless otherwise
stated. Statistical significancewas determined by a Student’s t test or ANOVA,
as appropriate, and a p-value of <0.05 was considered as significant.
Microarray Data Submission
Microarray data for human and zebrafish arrays have been submitted to the
Gene ExpressionOmnibus (GEO) and have been given a provisional accession
number: GSE12039.
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures and Sup-
plemental References, six supplemental tables, and nine supplemental figures
and are available with this article online at http://www.developmentalcell.com/
cgi/content/full/15/2/272/DC1/.
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